Galindo, MD, director of the Comprehensive Diabetes Center of the University of Miami Health System, and director of Diabetes Management at Jackson Memorial Health System, both in Miami, told Medscape Medical News that the findings match his clinical experience, noting, I believe its related to several factors, including more familiarity with the incretin therapies by the time of tirzepatide approval. And, Galindo added, tirzepatide generally has been shown to have higher glucose-lowering potency than semaglutide, although not [yet] via direct comparisons, and to be better tolerated based on his clinical experience
Retrieved from Nemeth V
Consider me a long-term fan of girl dinners, low effort snack plates that for me, consist of pasta, cheeses, and maybe a scoop of chicken
This approval is a significant step in increasing access to effective diabetes treatments